Kliničke studije za Лупус u državi Тексас
24 studija za Лупус traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
- Houston14 студија
- Dallas6 студија
- Mesquite4 студија
- Frisco4 студија
- San Antonio4 студија
- El Paso4 студија
- Arlington3 студија
- Allen3 студија
Zvanični tekst studije (na engleskom)
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Austin
- Research Site, Baytown
- Research Site, Colleyville
- и још 3
Тражи се учесникФаза 3
Узраст од 18 до 70 · Оба пола · Ажурирано 13. 11. 2026. · NCT07430306A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Amarillo Center for Clinical Research, Amarillo
- Precision Comprehensive Clinical Research Solutions - Colleyville, Colleyville
- Precision Comprehensive Clinical Research Solutions, Euless
- и још 4
Тражи се учесникФаза 2
Узраст од 18 до 74 · Оба пола · Ажурирано 12. 11. 2026. · NCT07409181Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04751396Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- и још 2
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03816345Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Novel Research LLC, Bellaire
- Accurate Clinical Research, League City
- Epic Medical Research, Red Oak
Тражи се учесникФаза 3
Узраст од 12 до 100 · Оба пола · Ажурирано 9. 11. 2026. · NCT06133972A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- North Texas Center for Clinical Research, Frisco
- Prolato Clinical Research Center, Houston
- Accurate Clinical Research, Humble
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT07355218A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Allen Arthritis, Allen
- Arthritis and Rheumatology Research Institute PLLC, Allen
- Arthritis Care of Texas, Corpus Christi
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT07332481A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Amarillo Medical Specialists Rheumatology, Amarillo
- Amarillo Center for Clinical Research, Amarillo
- Arthritis and Rheumatology Research Institute, Frisco
- и још 5
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 3. 11. 2026. · NCT07438496Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06434363A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Arthritis Care of Texas - Corpus Christi, Corpus Christi
- Lone Star Arthritis & Rheumatology Associates, P.C., Denton
- El Paso Medical Research Institute (MedResearch, Inc), El Paso
- и још 1
Тражи се учесникОпсервациона студија
Узраст 16 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT07175285A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50738, Bellaire
- Sl0044 50781, El Paso
- Sl0044 50673, Fort Worth
- и још 6
Тражи се учесникФаза 3
Узраст 16 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT06617325Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
- Texas Children's Hospital, Houston
- Texas Transplant Institute, San Antonio
Тражи се учесникФаза 2
Узраст од 12 до 65 · Оба пола · Ажурирано 30. 10. 2026. · NCT07053800Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Research Site, Allen
- Research Site, Mesquite
Тражи се учесникФаза 1
Узраст од 18 до 65 · Оба пола · Ажурирано 28. 10. 2026. · NCT07201558Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- Baylor College of Medicine, Houston
Тражи се учесникФаза 1
Узраст од 18 до 60 · Оба пола · Ажурирано 27. 10. 2026. · NCT06975787A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Stryde Research, Plano
- Tranquil Clinical Research, Webster
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 26. 10. 2026. · NCT06613360A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Accurate Clinical Research - Houston /ID# 278382, Houston
- Epic Medical Research /ID# 279180, Red Oak
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 20. 10. 2026. · NCT07607964RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Texas MD Anderson Cancer Center, Houston
Тражи се учесникФаза 1/2
Узраст од 12 до 65 · Оба пола · Ажурирано 6. 10. 2026. · NCT06121297An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, El Paso
- Research Site, Houston
Тражи се учесникФаза 3
Узраст од 5 до 17 · Оба пола · Ажурирано 30. 9. 2026. · NCT05835310A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- The University of Texas Southwestern Medical Center, Dallas
Тражи се учесникФаза 2
Узраст од 12 до 70 · Оба пола · Ажурирано 14. 9. 2026. · NCT07570862A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Integrative Rheumatology of South Texas - Harlingen /ID# 276458, Harlingen
Тражи се учесникФаза 1
Узраст од 18 до 75 · Оба пола · Ажурирано 10. 8. 2026. · NCT06977724A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
- Rheumatology Care Center, PLLC, Bellaire
- Texas Arthritis Center, El Paso
- Novel Research, LLC., Houston
- и још 3
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 30. 7. 2026. · NCT07201129A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
- US04-0, Irving
- US02-0, San Antonio
Тражи се учесникФаза 1/2Здраве особе су добродошле
Узраст од 18 до 70 · Оба пола · Ажурирано 2. 6. 2026. · NCT06625671Lupus Landmark Study: A Prospective Registry and Biorepository
- UT Southwestern Medical Center, Dallas
Тражи се учесникОпсервациона студија
Узраст од 18 до 110 · Оба пола · Ажурирано 15. 4. 2026. · NCT05934149A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
- Climb Bio Investigative Site #100104, Allen
- Climb Bio Investigative Site #100101, San Antonio
Тражи се учесникФаза 1
Узраст од 18 до 65 · Оба пола · Ажурирано 27. 3. 2026. · NCT07011043Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.